Answer
No incremental increase in adverse reactions was observed with concomitant bronchodilators or corticosteroids in the phase III palivizumab IMpact-RSV study in premature children and children with bronchopulmonary dysplasia, although no formal interaction studies were conducted.
Sources for this answer
- Synagis 50 mg/0.5 ml solution for injectionAstraZeneca UK Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 5Document updated
Sources checked